| Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen (NCT02097173) | medac GmbH | 2013-05-01 |
| Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (NCT02330380) | University Hospitals Cleveland Medical Center | 2013-04-01 |
| Vascular Inflammation in Psoriasis - Extension Study (NCT01866592) | University of Pennsylvania | 2013-04-01 |
| Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis (NCT01582932) | Mayne Pharma International Pty Ltd | 2013-04-01 |
| Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis (NCT01368887) | DermiPsor, Ltd. | 2013-04-01 |
| Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients (NCT01844973) | Maruho North America Inc. | 2013-04-01 |
| A Phase 3 Clinical Study of KHK4827 (NCT01782924) | Kyowa Kirin Co., Ltd. | 2013-03-01 |
| A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis (NCT01782664) | GlaxoSmithKline | 2013-03-01 |
| Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (NCT01812954) | Jochen Schmitt. | 2013-03-01 |
| Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis (NCT01836939) | Mark Lebwohl | 2013-03-01 |
| 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat (NCT03399526) | Bayer | 2013-02-11 |
| Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis (NCT02191020) | Xijing Hospital | 2013-02-01 |
| Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis (NCT02432040) | Philippine Dermatological Society | 2013-02-01 |
| A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis (NCT01901705) | China Medical University Hospital | 2013-02-01 |
| Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects (NCT01856647) | Rockefeller University | 2013-02-01 |
| An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis (NCT01782937) | Kyowa Kirin Co., Ltd. | 2013-02-01 |
| The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI) (NCT01778569) | National Heart, Lung, and Blood Institute (NHLBI) | 2013-01-22 |
| A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy (NCT01761019) | University of Pittsburgh | 2013-01-01 |
| Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis (NCT01745133) | Leon Kircik, M.D. | 2013-01-01 |
| TL1A Expression in Psoriatic Skin (NCT01744327) | Bispebjerg Hospital | 2012-12-01 |
| A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis (NCT01837420) | Vascular Biogenics Ltd. operating as VBL Therapeutics | 2012-11-01 |
| Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (NCT01722214) | Innovaderm Research Inc. | 2012-11-01 |
| Cromoglicate in Psoriasis (NCT01722812) | LEO Pharma | 2012-11-01 |
| A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers (NCT01702493) | Sirtris, a GSK Company | 2012-10-30 |
| Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis (NCT01714544) | Promius Pharma, LLC | 2012-10-01 |
| Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis (NCT01690299) | Amgen | 2012-10-01 |
| Using an Internet Study to Improve Adherence for Psoriasis Patients (NCT01802580) | Wake Forest University | 2012-10-01 |
| Influence of Atorvastatin on Psoriasis Severity and Endothelial Function (NCT01527097) | shmuel fuchs | 2012-08-01 |
| Study to Evaluate Broadlumab vs Placebo and Ustekinumab (NCT02786732) | MedDerm Associates | 2012-08-01 |
| Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (NCT01708590) | Bausch Health Americas, Inc. | 2012-08-01 |
| A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (NCT01646177) | Eli Lilly and Company | 2012-07-28 |
| Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis (NCT01617018) | Assistance Publique - Hôpitaux de Paris | 2012-07-01 |
| Vascular Inflammation in Psoriasis Trial (The VIP Trial) (NCT01553058) | University of Pennsylvania | 2012-07-01 |
| Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis (NCT01538342) | Centre Hospitalier Universitaire de Nice | 2012-07-01 |
| Haut-Tief Patient Education on Psoriasis and Eczema (NCT02205593) | University of Zurich | 2012-07-01 |
| The Effect of Alga Dunaliella Bardawil on Psoriasis (NCT01628081) | Sheba Medical Center | 2012-06-01 |
| TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis (NCT01657513) | University Hospital, Gentofte, Copenhagen | 2012-06-01 |
| Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis (NCT01661127) | Pusan National University Hospital | 2012-06-01 |
| A Study in Japanese Participants With Moderate-to-Severe Psoriasis (NCT01624233) | Eli Lilly and Company | 2012-06-01 |
| A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (NCT01597245) | Eli Lilly and Company | 2012-05-18 |
| A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis (NCT01700985) | Therapeutics, Inc. | 2012-05-01 |
| A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis (NCT01585233) | Astellas Pharma Global Development, Inc. | 2012-04-30 |
| A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis (NCT02274363) | Janssen Pharmaceutica | 2012-04-10 |
| Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis (NCT01563068) | Mayne Pharma International Pty Ltd | 2012-04-01 |
| Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis (NCT01577550) | AbbVie | 2012-04-01 |
| OTIS Cimzia Pregnancy Registry (NCT01797224) | University of California, San Diego | 2012-03-01 |
| A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis (NCT01519089) | Pfizer | 2012-03-01 |
| The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment (NCT01511315) | University of California, San Francisco | 2012-03-01 |
| A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (NCT01550744) | Janssen Biotech, Inc. | 2012-03-01 |
| Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg (NCT01539213) | Novartis Pharmaceuticals | 2012-02-01 |
| Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis (NCT03069144) | Haus Bioceuticals | 2012-01-06 |
| Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis (NCT02922192) | Biologics & Biosimilars Collective Intelligence Consortium | 2012-01-01 |
| Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients (NCT01687582) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-01-01 |
| Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors (NCT07041112) | Juan Ruano Ruiz | 2012-01-01 |
| Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis (NCT02107482) | Tufts Medical Center | 2011-12-01 |
| A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis (NCT01490632) | Eli Lilly and Company | 2011-12-01 |
| A Phase 3 Study in Participants With Moderate to Severe Psoriasis (NCT01474512) | Eli Lilly and Company | 2011-11-16 |
| A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (NCT01483599) | Janssen Inc. | 2011-11-10 |
| A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis (NCT01488201) | Kyowa Kirin Co., Ltd. | 2011-11-01 |
| Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis (NCT01439425) | Universita di Verona | 2011-11-01 |
| A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis (NCT01610596) | Therapeutics, Inc. | 2011-11-01 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis (NCT01493518) | Amgen | 2011-11-01 |
| Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis (NCT01384630) | Janssen Research & Development, LLC | 2011-09-30 |
| Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters (NCT01352780) | Oslo University Hospital | 2011-09-01 |
| A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis (NCT01484587) | Janssen Pharmaceutical K.K. | 2011-08-22 |
| Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (NCT01387815) | AbbVie (prior sponsor, Abbott) | 2011-08-16 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis (NCT01510951) | Amgen | 2011-08-01 |
| BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis (NCT01403012) | Technical University of Munich | 2011-08-01 |
| Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (NCT01429870) | University of Zurich | 2011-08-01 |
| Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test (NCT01462643) | Almirall, S.A. | 2011-08-01 |
| The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis (NCT01504113) | National Taiwan University Hospital | 2011-07-01 |
| Nicotinamide in the Treatment of Psoriasis (NCT01763424) | Isfahan University of Medical Sciences | 2011-07-01 |
| LEO 90105 Ointment in Japanese Subjects With Psoriasis (NCT01422434) | LEO Pharma | 2011-07-01 |
| Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis (NCT01404338) | Patel, Rita Vikram, M.D. | 2011-06-01 |
| Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab (NCT01328366) | AbbVie (prior sponsor, Abbott) | 2011-05-01 |
| Therapeutic Education Program in Psoriasis (NCT02310204) | University Hospital, Toulouse | 2011-05-01 |
| Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test (NCT01360944) | Almirall, S.A. | 2011-05-01 |
| Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study (NCT01382784) | Oslo University Hospital | 2011-05-01 |
| Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis (NCT01245140) | Stiefel, a GSK Company | 2011-04-26 |
| Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (NCT01316224) | AbbVie (prior sponsor, Abbott) | 2011-04-01 |
| Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis (NCT01313221) | Amgen | 2011-04-01 |
| Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. (NCT01320293) | University of North Carolina, Chapel Hill | 2011-03-01 |
| miRNAs and mRNAs in Psoriasis (NCT01604902) | University of Aarhus | 2011-03-01 |
| Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (NCT01356758) | University of Aarhus | 2011-03-01 |
| A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis (NCT01276639) | Pfizer | 2011-03-01 |
| A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis (NCT01309737) | Pfizer | 2011-03-01 |
| A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206) (NCT01276847) | Merck Sharp & Dohme LLC | 2011-03-01 |
| CP-690-550 Ointment For Chronic Plaque Psoriasis (NCT01246583) | Pfizer | 2011-02-16 |
| Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis (NCT01714284) | Centro Studi Gised | 2011-02-01 |
| Swiss Dermatology Network of Targeted Therapies (SDNTT) (NCT01706692) | Swiss Dermatology Network for Targeted Therapies | 2011-02-01 |
| AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis (NCT01300052) | Pfizer | 2011-01-26 |
| Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases (NCT01254240) | University of Zurich | 2010-12-01 |
| A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) (NCT01235728) | Merck Sharp & Dohme LLC | 2010-11-01 |
| Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis (NCT01223976) | Tel-Aviv Sourasky Medical Center | 2010-11-01 |
| A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis (NCT01241591) | Pfizer | 2010-11-01 |
| ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT01208090) | Actelion | 2010-10-31 |
| A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) (NCT01225731) | Merck Sharp & Dohme LLC | 2010-10-25 |
| A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. (NCT01262534) | Janssen-Cilag, S.A. | 2010-10-01 |
| Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis (NCT01265823) | AbbVie (prior sponsor, Abbott) | 2010-10-01 |
| Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? (NCT01228409) | Frankel, Amylynne, M.D. | 2010-10-01 |